Skip to main content

NDUFA13 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 2 and 73 bp insertion in exon 2 and 8 bp deletion in exon 2.

Be the first to review this product! Submit a review

Images

Western blot - Human NDUFA13 (GRIM19) knockout HeLa cell line (AB265863), expandable thumbnail
  • Western blot - Human NDUFA13 (GRIM19) knockout HeLa cell line (AB265863), expandable thumbnail
  • Sanger Sequencing - Human NDUFA13 (GRIM19) knockout HeLa cell line (AB265863), expandable thumbnail
  • Sanger Sequencing - Human NDUFA13 (GRIM19) knockout HeLa cell line (AB265863), expandable thumbnail
  • Sanger Sequencing - Human NDUFA13 (GRIM19) knockout HeLa cell line (AB265863), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 2 and 73 bp insertion in exon 2 and 8 bp deletion in exon 2

Alternative names

2700054G14Rik, AU022060, B16.6, CDA016, CGI-39, CGI39 protein, CI-B16.6, Cell death regulatory protein, Cell death regulatory protein GRIM-19, Complex I-B16.6, FLJ58045, FLJ59191, Gene associated with retinoic and IFN-induced mortality 19 protein, Gene associated with retinoic and interferon-induced mortality 19 protein, Gene associated with retinoic interferon induced mortality 19 protein, NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13, NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13, NADH-ubiquinone oxidoreductase B16.6 subunit, NDUAD_HUMAN, NDUFA13, RGD1565358

Recommended products

NDUFA13 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 2 and 73 bp insertion in exon 2 and 8 bp deletion in exon 2.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, 2 bp deletion in exon 2 and 73 bp insertion in exon 2 and 8 bp deletion in exon 2
Antibiotic resistance
Puromycin 1µg/mL
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
NDUFA13
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

GRIM19 also known as NDUFA13 is a small protein with a molecular mass of approximately 16 kDa. It expresses mainly in mitochondria where it forms an integral component of the mitochondrial respiratory chain complex I. GRIM19 plays an important role in the functioning of complex I by facilitating the assembly and stabilization of the complex enabling efficient electron transport and ATP synthesis.

Biological function summary

GRIM19 interacts with several complexes and proteins within the mitochondrial inner membrane. As a part of complex I also known as NADH:ubiquinone oxidoreductase it contributes to the initial step of mitochondrial oxidative phosphorylation. GRIM19 also participates in the regulation of apoptosis and its expression is influenced during cellular stress situations highlighting its significance in cellular survival and energy production.

Pathways

GRIM19 integrates closely with mitochondrial apoptosis and energy metabolism pathways. Its interactions within oxidative phosphorylation place it in concert with both the electron transport chain and the apoptosis regulatory network. GRIM19 shares associations with related proteins such as cytochrome c oxidase and other complex I subunits highlighting its essential contribution to these important biological processes.

Associated diseases and disorders

GRIM19 demonstrates links to various pathologies including cancer and mitochondrial diseases. Alterations in GRIM19 expression or function have been implicated in the progression of certain cancers such as colorectal and thyroid cancer where GRIM19's usual regulatory role in apoptosis can be disrupted. Additionally its involvement in mitochondrial disease connects to proteins like COX-A1 emphasizing the importance of maintaining functional complexes for cellular health.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

5 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com